[{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Loxo Oncology Inc \/ Eli Lilly"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Loxo Oncology Inc \/ Eli Lilly"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"Coiled-coil domain-containing protein 6\/Tyrosine-protein kinase receptor RET | Kinesin-1 heavy chain\/ Tyrosine-protein kinase receptor RET | Tyrosine-protein kinase receptor RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"15","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Loxo Oncology Inc \/ Eli Lilly"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Loxo Oncology Inc \/ Eli Lilly"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Loxo Oncology Inc \/ Eli Lilly"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Loxo-305","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"8","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Neurology","graph2":"Phase II","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Loxo Oncology Inc \/ Eli Lilly"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Loxo Oncology Inc \/ Eli Lilly"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"Coiled-coil domain-containing protein 6\/Tyrosine-protein kinase receptor RET | Kinesin-1 heavy chain\/ Tyrosine-protein kinase receptor RET | Tyrosine-protein kinase receptor RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"15","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Loxo-305","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Loxo Oncology Inc \/ Inapplicable"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Eli Lilly"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"Coiled-coil domain-containing protein 6\/Tyrosine-protein kinase receptor RET | Kinesin-1 heavy chain\/ Tyrosine-protein kinase receptor RET | Tyrosine-protein kinase receptor RET","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Eli Lilly"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Loxo-305","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Inapplicable"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Loxo-305","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Inapplicable"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"Coiled-coil domain-containing protein 6\/Tyrosine-protein kinase receptor RET | Kinesin-1 heavy chain\/ Tyrosine-protein kinase receptor RET | Tyrosine-protein kinase receptor RET","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Eli Lilly"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rosuvastatin Calcium","moa":"HMG-CoA reductase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Eli Lilly"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LY3410738","moa":"Oxalosuccinate decarboxylase (IDH1)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"Coiled-coil domain-containing protein 6\/Tyrosine-protein kinase receptor RET | Kinesin-1 heavy chain\/ Tyrosine-protein kinase receptor RET | Tyrosine-protein kinase receptor RET","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Eli Lilly"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"Coiled-coil domain-containing protein 6\/Tyrosine-protein kinase receptor RET | Kinesin-1 heavy chain\/ Tyrosine-protein kinase receptor RET | Tyrosine-protein kinase receptor RET","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"Coiled-coil domain-containing protein 6\/Tyrosine-protein kinase receptor RET | Kinesin-1 heavy chain\/ Tyrosine-protein kinase receptor RET | Tyrosine-protein kinase receptor RET","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"Coiled-coil domain-containing protein 6\/Tyrosine-protein kinase receptor RET | Kinesin-1 heavy chain\/ Tyrosine-protein kinase receptor RET | Tyrosine-protein kinase receptor RET","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"Coiled-coil domain-containing protein 6\/Tyrosine-protein kinase receptor RET | Kinesin-1 heavy chain\/ Tyrosine-protein kinase receptor RET | Tyrosine-protein kinase receptor RET","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"Coiled-coil domain-containing protein 6\/Tyrosine-protein kinase receptor RET | Kinesin-1 heavy chain\/ Tyrosine-protein kinase receptor RET | Tyrosine-protein kinase receptor RET","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"Coiled-coil domain-containing protein 6\/Tyrosine-protein kinase receptor RET | Kinesin-1 heavy chain\/ Tyrosine-protein kinase receptor RET | Tyrosine-protein kinase receptor RET","graph1":"Nephrology","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Repaglinide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Selpercatinib","moa":"Coiled-coil domain-containing protein 6\/Tyrosine-protein kinase receptor RET | Kinesin-1 heavy chain\/ Tyrosine-protein kinase receptor RET | Tyrosine-protein kinase receptor RET","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Repaglinide","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LY3410738","moa":"Oxalosuccinate decarboxylase (IDH1)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LY3410738","moa":"Oxalosuccinate decarboxylase (IDH1)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Nephrology","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2022","type":"Inapplicable","leadProduct":"14-C Selpercatinib","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LY3537982","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LY3537982","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LOXO-783","moa":"ESR1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LOXO-783","moa":"ESR1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LY3537982","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2023","type":"Inapplicable","leadProduct":"14-C LOXO-305","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Foghorn Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Loxo Oncology Inc","amount2":0.38,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.38,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"3","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Loxo Oncology Inc \/ Inapplicable"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LOXO-260","moa":"FGFR2","graph1":"Oncology","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Loxo Oncology Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"8","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Loxo-305","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loxo Oncology Inc \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Loxo Oncology Inc \/ Eli Lilly"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2023","type":"Inapplicable","leadProduct":"14-C LY3537982","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Loxo Oncology Inc","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2023","type":"Inapplicable","leadProduct":"14-C LOXO-783","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Loxo Oncology Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loxo Oncology Inc \/ Loxo Oncology Inc","highestDevelopmentStatusID":"6","companyTruncated":"Loxo Oncology Inc \/ Loxo Oncology Inc"}]
Find Clinical Drug Pipeline Developments & Deals by Loxo Oncology Inc
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
